Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Kidney Cancer
  •  Neoadjuvant Therapy
  •  Urological Cancers
  •  Cervical Cancer
  •  Blood Cancer
  •  Central Nervous System Tumors
  •  Breast Cancer
  •  Chemotherapy and Radiotherapy

Abstract

Citation: Clin Oncol. 2023;8(1):2009.DOI: 10.25107/2474-1663.2009

NDFIP1 as a Diagnostic Biomarker, Correlated with Immune Infiltrates in Breast Cancer

Xu X, Yin K, Zhang Y and Lin X

Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China
Department of Pathophysiology, Shandong First Medical University, Shandong Academy of Medical Sciences, China
Department of Pathology, Shandong Provincial Hospital, Shandong University, China

*Correspondance to: Yueying Zhang 

 PDF  Full Text Research Article | Open Access

Abstract:

NDFIP1, an E3 ubiquitin ligase, plays a key role in multiple cancers. However, there is no detailed report on the role of NDFIP1 in Breast Cancer (BRCA). In this study, we used the Cancer Genome Atlas (TCGA) database to analyze the function of NDFIP1 in BRCA. NDFIP1 expression in clinical samples and cell lines was then validated using quantitative real-time PCR and immunohistochemistry. The ability of cells to proliferate, migrate and invade was determined with Cell Counting Kit-8 (CCK8), Transwell and wounding heal assays respectively. The results indicate that NDFIP1 expression was down-regulated and associated with the clinical characteristics of BRCA patients. In addition, the expression of NDFIP1 predicted poor immunotherapy response in specific patient groups; high NDFIP1 expression patients were with worse prognosis in four groups (CTLA4-PD1-, CTLA4-PD1+, CTLA4+PD1-, CTLA4+PD1+). Silencing NDFIP1, promoted the proliferation ability, migration ability and invasion ability of MCF-7 cells, MCF-7/ADM cells and MDA-MB-231 cells. In conclusion, NDFIP1 is a potential prognostic marker that can be used to determine immune infiltrates and BRCA's progress.

Keywords:

Bioinformatics; Breast cancer; NDFIP1; Prognosis; Immune infiltrates

Cite the Article:

Xu X, Yin K, Zhang Y, Lin X. NDFIP1 as a Diagnostic Biomarker, Correlated with Immune Infiltrates in Breast Cancer. Clin Oncol. 2023;8:2009..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

High CDX2 Expression Predicts a Favorable Prognosis in Patients with Early-Stage Gastric Adenocarcinoma
 Abstract  PDF  Full Text
Breast MR Imaging Helps Differentiate Malignant and Benign Mammographic Microcalcifications: A Study Based on the 5th Edition of BI-RADS
 Abstract  PDF  Full Text
View More...